VRTX241206P415000
- 1.35
- -0.35-20.59%
Vertex Pharmaceuticals Newsroom
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $506
RBC Capital Sticks to Their Hold Rating for Vertex Pharmaceuticals (VRTX)
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Redburn Atlantic Adjusts Vertex Pharmaceuticals Price Target to $570 From $560
Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $486
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
Vertex Pharmaceuticals (VRTX) Receives a Hold From Stifel Nicolaus
Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $490
Vertex Pharmaceuticals Analyst Ratings
Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $575
Vertex Pharmaceuticals Initiated With a Buy at Citi
Argus Raises Price Target on Vertex Pharmaceuticals to $550 From $530
Vertex Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $503
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $408
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $486 to $600
Vertex Pharmaceuticals: Strong Financial Performance and Innovative Drug Pipeline Underpin Buy Rating
Vertex Pharmaceuticals Price Target Raised to $486.00/Share From $480.00 by Scotiabank
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley